Regenon 25mg



Regenon Retard 60mg is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone.


Regenon is recommended for patients with a higher than normal weight who have not managed to lose weight
weight only with a dietary regime and in which another, organic, cause of obesity was excluded.
It is recommended that treatment with Regenon be part of a more complex treatment of obesity that
includes dietary regimen, physical activity and psychological counseling.


Do not use Regenon:
– if you are allergic to amfepramone hydrochloride or any of the other components of this medicine.

Before using Regenon, talk to your doctor or pharmacist.


Pregnancy, breast-feeding and fertility:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to become pregnant, ask your doctor or pharmacist for advice before taking this medicine.
Regenon should not be used during pregnancy and breastfeeding.
It is recommended that during treatment with Regenon you use contraceptive methods to avoid pregnancy.
Make sure you are not pregnant before starting treatment with Regenon.


Driving vehicles and using machines:
Even if Regenon is administered according to the doctor’s instructions, the ability to react may change to such an extent that it negatively affects the ability to drive vehicles or use machines. This effect is increased when the drug is combined with ethyl alcohol.
For this reason, driving vehicles, using machinery or carrying out activities with a high degree of danger must be avoided at least during the first days of treatment. The decision will be made by the doctor depending on the individual reactivity and the administered dose


Administration Method:

Always use this medicine exactly as your doctor or pharmacist has told you. Talk to your doctor or pharmacist if you are not sure.

Adults and children over 12 years of age:
1 soft capsule 3 times a day. The maximum daily dose is 3 soft capsules.

Children under 12 years of age:
Regenon is contraindicated in this category of patients.


Way Of Usage:

Regenon capsules should be swallowed whole, with liquid, before main meals.
The administration of the medicine in the evening should be avoided because the medicine can cause restlessness and insomnia. The last administration must be at least 4 hours before bedtime.
It is recommended that the treatment be done under the supervision of a doctor experienced in treating obesity.
Before prescribing this medicine, secondary organic causes of obesity must be excluded by diagnosis.
Treatment of obesity can only be done in the case of a global approach that must include diet, medical and psychotherapeutic methods.


Duration Of Treatment:

The duration of treatment is 4 – 6 weeks and should not exceed 3 months.
If no reduction in weight is observed after 3-4 weeks, therapy should be discontinued. Even in case of weight loss during this period, the drug should not be taken for more than 12 weeks.
The duration of treatment will be determined by your doctor.
Please contact your doctor or pharmacist if you think the effect of Regenon is too strong or too weak.

If you have any further questions about this medicine, ask your doctor or pharmacist.



– The active substance is amfepramone hydrochloride. Each tablet contains 25 mg of amfepramone hydrochloride.
– The other components are: tartaric acid, solid paraffin (freezing point 68-72o C), liquid paraffin
(low viscosity), aluminum stearate, glutamic acid hydrochloride, colloidal anhydrous silicon dioxide;
capsule – gelatin, glycerol (85%), sorbitol, mannitol (E 421), hydrolyzed hydrogenated starch, red iron oxide (E 172), 3-ethoxy-4-hydroxybenzaldehyde, phosphoric acid (85%).

60 soft capsules


Read the leaflet carefully and completely before you start using this medicine because it contains important information for you.

Additional information


60 Pills, 100 Pills, 250 Pills, 500 Pills, 1000 Pills


There are no reviews yet.

Be the first to review “Regenon 25mg”

Your email address will not be published. Required fields are marked *